CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 274 enrolled
Drug / intervention
Littmann ®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03503188
NCT03503188Phase 4Completed

Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim·interventional·Posted Apr 19, 2018·Updated Jan 27, 2020

In Brief

A Phase 4 clinical trial evaluating Littmann ® for Idiopathic Pulmonary Fibrosis. Completed, enrolled 274 participants across 10 sites.

Detailed Summary

The aim of this study is the data collection for patients with IPF and symptom matched controls to create a database of lung auscultation sounds and basic patient characteristics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 19, 2018
Enrollment StartMar 28, 2018
Primary CompletionJan 3, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.2 years ago

Interventions

Littmann ®device

electronic stethoscope